The investigation of the 50% effective dose of dexmedetomidine in general anesthesia induction

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100046916

Enrollment

Unknown

Registered

2021-05-30

Start date

2021-06-14

Completion date

Unknown

Last updated

2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

Experimental group:Use dexmedetomidine to induce general anesthesia

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years; 2. ASA I-II level; 3. Elective abdominal surgery.

Exclusion criteria

Exclusion criteria: 1. Anemia, hemoglobin 30kg/m^2; 3. Brady sinus (HR<50bpm) or high heart block (II degree type 2 or III degree); 4. Heart failure, LVEF<50%; 5. Liver and kidney dysfunction; 6. Infection of the whole body or vital organs; 7. Long-term use of alpha receptor blockers to lower blood pressure; 8. Long-term use of psychotropic drugs, anti-epileptics or analgesics; 9. Transition to laparotomy, or excessive bleeding during surgery and need for blood transfusion; 10. Alcoholism; 11. Have a history of allergy to the anesthetic drugs used in this study.

Design outcomes

Primary

Measure	Time frame
50% effective dose;	—

Secondary

Measure	Time frame
Heart rate during the induction period;Blood pressure during the induction period;The depth of anesthesia during anesthesia induction;Induction time;	—

Countries

China

Contacts

Public ContactNi Cheng

Cancer Hospital, Chinese Academy of Medical Sciences

nicheng83@163.com+86 13681569807

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026